Italia markets close in 8 hours 20 minutes

Novartis AG (NVSEF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
85,45+1,45 (+1,73%)
Alla chiusura: 01:23PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente84,00
Aperto84,62
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno84,62 - 85,45
Intervallo di 52 settimane78,78 - 95,00
Volume978
Media Volume26.975
Capitalizzazione192,859B
Beta (5 anni mensile)0,56
Rapporto PE (ttm)19,74
EPS (ttm)4,33
Prossima data utiliN/D
Rendimento e dividendo (forward)3,22 (3,77%)
Data ex dividendo04 mar 2021
Stima target 1AN/D
  • GlobeNewswire

    Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil

  • GlobeNewswire

    Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

    Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight daysThe secondary endpoint of hospitalization and/or ER visits related to COVID-19, or death showed an overall 78% reduction in risk of events across ensovibep arms compared to placeboA total of 407 patients were recruited in the Phase 2 stud

  • GlobeNewswire

    Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent

    Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosing regimen for Gilenya. In August 2020, the U.S. Federal District Court for the District of Delaware issued a favorable decision in the Gilenya patent litigation and a permanent injunction was granted against HEC Pharma until the expiration of the ‘405 patent in December 2027 (including pediatric excl